Irbesartan and hydrochlorothiazide association in the treatment of hypertension
- PMID: 19355995
- DOI: 10.2174/157016109787455644
Irbesartan and hydrochlorothiazide association in the treatment of hypertension
Abstract
Blood pressure (BP) is one of the most important and common vascular risk factors but it is often poorly controlled. Inhibition of the renin-angiotensin-aldosterone system (RAAS) provides beneficial effects in hypertensives. The association of low-dosed diuretics in combination with RAAS blocking agents allows maximum benefit from potassium depletion and control of compensatory increase in renin secretion, so increasing the efficacy and safety of RAAS blockers. Irbesartan is a potent and selective angiotensin II subtype 1 receptor antagonist indicated for use in patients with hypertension, including those with type 2 diabetes mellitus and nephropathy. Once-daily irbesartan administration provides 24h control of BP. In patients with mild-to-moderate hypertension, irbesartan was as effective as enalapril, atenolol and amlodipine, and more effective than losartan and valsartan in terms of absolute reduction in BP and response rate. Irbesartan also induced regression of left ventricular hypertrophy. Moreover, irbesartan 300 mg/day exerts a significant renoprotective effect in hypertensive type 2 diabetic patients. The relative risk of doubling of serum creatinine was significantly lower with irbesartan than amlodipine or placebo. Irbesartan was also effective in non-diabetic nephropatic patients. Moreover, irbesartan has peroxisome proliferator-activated receptor agonistic effects in in vitro studies, and it also demonstrated beneficial effects on inflammatory markers of atherosclerosis and endothelial function. The overall incidence of adverse events is similar to that of placebo. A fixed dose of hydrochlorothiazide (HCTZ) and irbesartan shows additive antihypertensive effect in a dose dependent manner up to HCTZ 25 mg and irbesartan 300 mg with high tolerability in diverse patient groups. Combination effects on end organ protection must be evaluated by broad spectrum studies. Ongoing trials about irbesartan and its combination with diuretics may provide necessary data to interpret the value of this association among others.
Comment in
-
Angiotensin, the hormone to be blocked by antithypertensive drugs, and perhaps why they don't work.Curr Vasc Pharmacol. 2009 Oct;7(4):549. doi: 10.2174/157016109789043874. Curr Vasc Pharmacol. 2009. PMID: 19863479 No abstract available.
Similar articles
-
Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy.Drugs. 2004;64(9):999-1028. doi: 10.2165/00003495-200464090-00011. Drugs. 2004. PMID: 15101793 Review.
-
Fixed combination of irbesartan and hydrochlorothiazide in the management of hypertension.Vasc Health Risk Manag. 2009;5(1):213-24. doi: 10.2147/vhrm.s3302. Epub 2009 Apr 8. Vasc Health Risk Manag. 2009. PMID: 19436667 Free PMC article. Review.
-
Safety and tolerability of fixed-dose irbesartan/hydrochlorothiazide for rapid control of severe hypertension.Clin Exp Hypertens. 2009 Oct;31(7):572-84. doi: 10.3109/10641960902929420. Clin Exp Hypertens. 2009. PMID: 19886855 Clinical Trial.
-
[Irbesartan in clinical practice].Kardiologiia. 2012;52(11):66-74. Kardiologiia. 2012. PMID: 23237398 Review. Russian.
-
Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension.Am J Hypertens. 1998 Apr;11(4 Pt 1):462-70. doi: 10.1016/s0895-7061(97)00501-3. Am J Hypertens. 1998. PMID: 9607385 Clinical Trial.
Cited by
-
A real-world pharmacovigilance analysis of adverse events associated with irbesartan using the FAERS and JADER databases.Front Pharmacol. 2024 Nov 20;15:1485190. doi: 10.3389/fphar.2024.1485190. eCollection 2024. Front Pharmacol. 2024. PMID: 39635439 Free PMC article.
-
Quantitative Estimation of Anti Hypertension Combination by Ratio Subtraction Spectrophotometry Method.Open Access Maced J Med Sci. 2019 Aug 30;7(17):2940-2946. doi: 10.3889/oamjms.2019.750. eCollection 2019 Sep 15. Open Access Maced J Med Sci. 2019. PMID: 31844461 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical